Kestra Medical Technologies Ltd. (KMTS) Stock Forecast & Price Target

Compare

16 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

KMTS Analyst Ratings

Strong Buy

5 Buy

1 Hold

0 Sell

Based on 6 analysts giving stock ratings to

Kestra

Medical Technologies Ltd.

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

KMTS Stock 12 Month Forecast

Average Price Target

$29.00

▲(26.91% Upside)

Based on 6 Wall Street analysts offering 12 month price targets for Kestra Medical Technologies Ltd. in the last 3 months. The average price target is $29.00 with a high forecast of $32.00 and a low forecast of $24.00. The average price target represents a 26.91% change from the last price of $22.85.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"14":"$14","33":"$33","18.75":"$18.75","23.5":"$23.5","28.25":"$28.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":32,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$32.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":29,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$29.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$24.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[14,18.75,23.5,28.25,33],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.52,26.94153846153846,27.36307692307692,27.784615384615385,28.206153846153846,28.627692307692307,29.049230769230768,29.470769230769232,29.892307692307693,30.313846153846153,30.735384615384614,31.15692307692308,31.57846153846154,{"y":32,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.52,26.71076923076923,26.90153846153846,27.092307692307692,27.283076923076923,27.473846153846154,27.664615384615384,27.855384615384615,28.046153846153846,28.236923076923077,28.427692307692308,28.61846153846154,28.80923076923077,{"y":29,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.52,26.326153846153847,26.13230769230769,25.93846153846154,25.744615384615383,25.55076923076923,25.356923076923078,25.163076923076922,24.96923076923077,24.775384615384617,24.58153846153846,24.38769230769231,24.193846153846152,{"y":24,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":20.99,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":20.99,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":20.99,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.58,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.96,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.68,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.84,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.38,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.12,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.15,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.38,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.69,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.52,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$32.00

Average Price Target$29.00

Lowest Price Target$24.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

David Roman

Goldman Sachs

$27→$24

Hold

5.03%

Upside

Reiterated

01/16/26

Kestra Medical price target lowered to $24 from $27 at Goldman SachsKestra Medical price target lowered to $24 from $27 at Goldman Sachs

Travis Steed

Bank of America Securities

$30

Buy

31.29%

Upside

Reiterated

01/15/26

Analysts Are Bullish on Top Healthcare Stocks: Caribou Biosciences (CRBU), Phathom Pharmaceuticals (PHAT)

Larry Biegelsen

Wells Fargo

$28

Buy

22.54%

Upside

Reiterated

01/14/26

Wells Fargo Keeps Their Buy Rating on Kestra Medical Technologies Ltd. (KMTS)

Rick Wise

Stifel Nicolaus

$28→$30

Buy

31.29%

Upside

Reiterated

12/12/25

Kestra Medical price target raised to $30 from $28 at StifelKestra Medical price target raised to $30 from $28 at Stifel

Matthew O'Brien

Piper Sandler

$27→$30

Buy

31.29%

Upside

Reiterated

12/12/25

Kestra Medical price target raised to $30 from $27 at Piper SandlerKestra Medical price target raised to $30 from $27 at Piper Sandler

Marie Thibault

BTIG

$32

Buy

40.04%

Upside

Reiterated

12/12/25

Kestra Medical Technologies Ltd. (KMTS) Receives a Buy from BTIG

Michael Polark

Wolfe Research

$29

Buy

26.91%

Upside

Initiated

03/31/25

Kestra Medical Technologies: Positioned for Growth in the Wearable Cardioverter Defibrillator Market

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

David Roman

Goldman Sachs

$27→$24

Hold

5.03%

Upside

Reiterated

01/16/26

Kestra Medical price target lowered to $24 from $27 at Goldman SachsKestra Medical price target lowered to $24 from $27 at Goldman Sachs

Travis Steed

Bank of America Securities

$30

Buy

31.29%

Upside

Reiterated

01/15/26

Analysts Are Bullish on Top Healthcare Stocks: Caribou Biosciences (CRBU), Phathom Pharmaceuticals (PHAT)

Larry Biegelsen

Wells Fargo

$28

Buy

22.54%

Upside

Reiterated

01/14/26

Wells Fargo Keeps Their Buy Rating on Kestra Medical Technologies Ltd. (KMTS)

Rick Wise

Stifel Nicolaus

$28→$30

Buy

31.29%

Upside

Reiterated

12/12/25

Kestra Medical price target raised to $30 from $28 at StifelKestra Medical price target raised to $30 from $28 at Stifel

Matthew O'Brien

Piper Sandler

$27→$30

Buy

31.29%

Upside

Reiterated

12/12/25

Kestra Medical price target raised to $30 from $27 at Piper SandlerKestra Medical price target raised to $30 from $27 at Piper Sandler

Marie Thibault

BTIG

$32

Buy

40.04%

Upside

Reiterated

12/12/25

Kestra Medical Technologies Ltd. (KMTS) Receives a Buy from BTIG

Michael Polark

Wolfe Research

$29

Buy

26.91%

Upside

Initiated

03/31/25

Kestra Medical Technologies: Positioned for Growth in the Wearable Cardioverter Defibrillator Market

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Kestra Medical Technologies Ltd.

3 Months

xxx

Success Rate

3/6 ratings generated profit

Average Return

+5.23%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +5.23% per trade.

1 Year

Rick WiseStifel Nicolaus

Success Rate

3/6 ratings generated profit

Average Return

+12.12%

reiterated a buy rating last month

Copying Rick Wise's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +12.12% per trade.

2 Years

xxx

Success Rate

3/6 ratings generated profit

Average Return

+12.12%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 50.00% of your transactions generating a profit, with an average return of +12.12% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

KMTS Analyst Recommendation Trends

Rating

Sep 25

Oct 25

Nov 25

Dec 25

Jan 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, KMTS has received 9 Buy Ratings, 27 Hold Ratings, and 0 Sell Ratings. KMTS average Analyst price target in the past 3 months is 29.00.

Each month's total comprises the sum of three months' worth of ratings.

KMTS Financial Forecast

KMTS Earnings Forecast

Next quarter’s earnings estimate for KMTS is -$0.60 with a range of -$0.64 to -$0.55. The previous quarter’s EPS was -$0.64. KMTS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year KMTS has Performed in-line its overall industry.

KMTS Sales Forecast

Next quarter’s sales forecast for KMTS is $22.87M with a range of $22.45M to $23.02M. The previous quarter’s sales results were $22.57M. KMTS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year KMTS has Performed in-line its overall industry.

KMTS Stock Forecast FAQ

What is KMTS’s average 12-month price target, according to analysts?

Based on analyst ratings, Kestra Medical Technologies Ltd.’s 12-month average price target is 29.00.

What is KMTS’s upside potential, based on the analysts’ average price target?

Kestra Medical Technologies Ltd. has 26.91% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is KMTS a Buy, Sell or Hold?

Kestra Medical Technologies Ltd. has a consensus rating of Strong Buy which is based on 5 buy ratings, 1 hold ratings and 0 sell ratings.

What is Kestra Medical Technologies Ltd.’s price target?

The average price target for Kestra Medical Technologies Ltd. is 29.00. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $32.00 ,the lowest forecast is $24.00. The average price target represents 26.91% Increase from the current price of $22.85.

What do analysts say about Kestra Medical Technologies Ltd.?

Kestra Medical Technologies Ltd.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.

How can I buy shares of KMTS?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Kestra Medical Technologies Ltd. (KMTS) Stock Forecast & Price Target

KMTS Analyst Ratings

KMTS Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Kestra Medical Technologies Ltd.

KMTS Analyst Recommendation Trends

KMTS Financial Forecast

KMTS Earnings Forecast

KMTS Sales Forecast

KMTS Stock Forecast FAQ

Detailed List of Analyst Forecasts